Johnson
BioSpace,
New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to…
New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to…
PR Newswire TITUSVILLE, N.J., Oct. 24, 2024 New five-year data reinforce long-term safety and efficacy of SPRAVATO®(esketamine…
New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to…
New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to…